🇫🇷 IPN.PA — Ipsen S.A.

Salud Mantener
← Volver

Precio actual

155,80 EUR

Máx. histórico

172,90

182 días

Caída desde máximo

-9,89%

Rango 52 semanas

115,60 – 174,00

Variación hoy

+1,70%

Cierre anterior

153,20

Rango de hoy

153,30 – 155,90

Volumen hoy

107.342

Peor caída histórica

-75,62%

30/08/2018 → 18/03/2020

Recuperado en 2157 días

Volatilidad anualizada ⓘ

30,51%

Información
Nombre completo
Ipsen S.A.
Divisa
EUR
Mercado
Paris
Sector
Salud
Industria
Drug Manufacturers - Specialty & Generic
Empleados
5.535
PER ⓘ
25,21 (puede no estar actualizado)
Dividend yield
1,04% (puede no estar actualizado)
Precio objetivo analistas
161,92 EUR (puede no estar actualizado)
Primera cotización
07/12/2005
Precio actualizado
hace 18 horas
Sobre la empresa

Ipsen S.A., a biopharmaceutical company, develops and commercializes medicines in the areas of oncology, rare disease, and neuroscience in North America, Europe, and internationally. It engages in the development of Somatuline for neuroendocrine tumors and acromegaly indications; and Dysport for motor muscular disorders and medical aesthetics indications; and Decapeptyl for advanced metastatic prostate cancer, uterine fibroids, central precocious puberty, endometriosis, female infertility, and early-stage breast cancer in combination with hormone therapy. The company also develops Cabometyx for renal cell carcinoma, second line hepatocellular carcinoma, differentiated thyroid cancer, and neuroendocrine tumors; Onivyde for second-line metastatic pancreatic cancer; and Bylvay for the treatment of progressive familial intrahepatic cholestasis and cholestatic pruritus in patients with both PFIC and Alagille syndrome. In addition, it is involved in the development of Iqirvo for the second line treatment for primary biliary cholangitis; Sohonos for the treatment to reduce new, abnormal bone formation in soft and connective tissues, in people living with ultra-rare bone disease, and fibrodysplasia ossificans progressiva; and IPN60340 in Phase I/II clinical trial for first line acute myeloid leukemia indications. Further, the company develops Tazverik + rituximab and lenalidomide in Phase III clinical trials for second line follicular lymphoma indications; Tovorafenib in Phase III clinical trials for first line pediatric low-grade gliomas indications; and IPN01194, IPN01195, IPN60300, and IPN01203 in Phase I for solid tumors indications; and IPN10200 in Phase II clinical trials for aesthetic and therapeutic indications. Ipsen S.A. was founded in 1929 and is headquartered in Paris, France.

Dividendos repartidos Total últimos 12 meses: 1,6000 EUR · Yield: 1,03%
Fecha de pago Importe por participación
03/06/2026 1,6000 EUR
04/06/2025 1,4000 EUR
30/05/2024 1,2000 EUR
02/06/2023 1,2000 EUR
31/05/2022 1,2000 EUR
31/05/2021 1,0000 EUR
03/06/2020 1,0000 EUR
31/05/2019 1,0000 EUR
04/06/2018 1,0000 EUR
09/06/2017 0,8500 EUR
02/06/2016 0,8500 EUR
29/05/2015 0,8500 EUR
09/06/2014 0,8000 EUR
05/06/2013 0,8000 EUR
06/06/2012 0,8000 EUR
Rentabilidad mensual
Evolución
Histórico día a día
Fecha Apertura Máximo Mínimo Cierre Variación Volatilidad día Volumen
10/03/2014 32,71 32,89 32,12 32,45 -0,37% 2,35% 50.673
07/03/2014 32,68 33,25 32,42 32,57 -0,11% 2,54% 79.309
06/03/2014 32,40 32,73 32,29 32,60 +0,77% 1,36% 75.797
05/03/2014 32,36 32,65 32,11 32,35 +0,15% 1,67% 68.738
04/03/2014 31,80 32,40 31,70 32,30 +2,22% 2,20% 112.900
03/03/2014 31,14 31,71 30,61 31,60 +1,49% 3,53% 322.624
28/02/2014 31,78 32,30 30,57 31,14 -0,18% 5,46% 136.646
27/02/2014 31,40 31,59 31,00 31,19 +0,06% 1,86% 73.621
26/02/2014 31,39 31,50 31,17 31,17 -0,59% 1,05% 45.642
25/02/2014 31,09 31,50 30,90 31,36 +0,92% 1,93% 67.318
24/02/2014 31,10 31,19 30,60 31,07 -0,03% 1,91% 91.402
21/02/2014 31,60 31,60 31,03 31,08 -1,18% 1,80% 37.546
20/02/2014 31,44 31,60 31,09 31,45 +0,16% 1,62% 39.791
19/02/2014 31,30 31,68 31,15 31,40 +0,32% 1,71% 42.241
18/02/2014 31,40 31,40 30,91 31,30 -0,16% 1,58% 53.293
17/02/2014 31,45 31,57 31,25 31,35 -0,37% 1,00% 23.916
14/02/2014 31,49 32,00 31,46 31,47 -0,06% 1,71% 58.573
13/02/2014 30,63 31,63 30,63 31,49 +2,82% 3,28% 125.450
12/02/2014 30,29 30,84 30,29 30,62 +1,22% 1,82% 54.423
11/02/2014 30,40 30,80 30,16 30,25 -0,23% 2,12% 42.485
10/02/2014 30,49 30,53 30,13 30,32 -0,16% 1,31% 33.704
07/02/2014 30,51 30,94 30,10 30,37 +1,03% 2,74% 69.915
06/02/2014 29,80 30,06 28,95 30,06 +1,50% 3,72% 95.986
05/02/2014 30,72 30,82 29,62 29,62 -2,93% 3,91% 85.305
04/02/2014 30,60 30,82 30,51 30,51 -0,10% 1,00% 34.978
03/02/2014 31,30 31,40 30,53 30,54 -1,88% 2,80% 61.852
31/01/2014 30,70 31,13 30,61 31,13 +1,52% 1,68% 60.866
30/01/2014 30,35 30,70 30,34 30,66 +1,14% 1,19% 57.021
29/01/2014 30,80 31,06 30,22 30,32 -1,25% 2,73% 57.273
28/01/2014 31,00 31,13 30,68 30,70 -0,98% 1,47% 88.624